

## Supplemental Digital Content 11

**TABLE: Clinical Response at Late Follow-Up Visit (Micro-ITT Analysis Set)**

Cohort	Clinical response, n (%)									
	1: ≥12 years to <18 years		2: ≥6 years to <12 years		3: ≥2 years to <6 years		4: ≥3 months to <2 years		All cohorts	
Outcome	Ceftazidime- avibactam (N = 9)	Cefepime (N = 3)	Ceftazidime- avibactam (N = 13)	Cefepime (N = 5)	Ceftazidime- avibactam (N = 10)	Cefepime (N = 5)	Ceftazidime- avibactam (N = 22)	Cefepime (N = 10)	Ceftazidime- avibactam (N = 54)	Cefepime (N = 23)
Favorable outcome	7 (77.8)	3 (100)	10 (76.9)	5 (100)	8 (80.0)	4 (80.0)	19 (86.4)	7 (70.0)	44 (81.5)	19 (82.6)
95% CI*	(45.6, 95.1)	(46.4, 100)	(50.3, 93.0)	(62.1, 100)	(49.7, 95.6)	(37.1, 97.7)	(67.9, 96.0)	(39.4, 90.7)	(69.6, 90.1)	(63.8, 93.8)
Sustained clinical cure	7 (77.8)	3 (100)	10 (76.9)	5 (100)	8 (80.0)	4 (80.0)	19 (86.4)	7 (70.0)	44 (81.5)	19 (82.6)
Clinical relapse	0	0	1 (7.7)	0	1 (10.0)	0	2 (9.1)	0	4 (7.4)	0
Clinical outcome at LFU not assessed because patient not clinical cure at TOC	2 (22.2)	0	2 (15.4)	0	1 (10.0)	1 (20.0)	1 (4.5)	3 (30.0)	6 (11.1)	4 (17.4)

\*A 2-sided 95% CI computed using Jeffreys method.

CI, confidence interval; LFU, late follow-up visit; TOC, test-of-cure.